Company profile AKRO
After 39 days of this quarter the interest is at 48.0. Based on that we can calculate that during remaining 52 days it will total up to 112.0. Akero Therapeutics expected interest is significantly lower compared to previous quarter (-45.4%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 45 | 123 173.3% QoQ | 141 14.6% QoQ | 99 -29.8% QoQ |
| 2020 | 164 264.4% YoY 65.7% QoQ | 171 39.0% YoY 4.3% QoQ | 117 -17.0% YoY -31.6% QoQ | 86 -13.1% YoY -26.5% QoQ |
| 2021 | 48 -70.7% YoY -44.2% QoQ | 137 -19.9% YoY 185.4% QoQ | 72 -38.5% YoY -47.4% QoQ | 72 -16.3% YoY 0.0% QoQ |
| 2022 | 39 -18.8% YoY -45.8% QoQ | 85 -38.0% YoY 117.9% QoQ | 168 133.3% YoY 97.6% QoQ | 108 50.0% YoY -35.7% QoQ |
| 2023 | 104 166.7% YoY -3.7% QoQ | 86 1.2% YoY -17.3% QoQ | 118 -29.8% YoY 37.2% QoQ | 205 89.8% YoY 73.7% QoQ |
| 2024 | 48 -53.8% YoY -76.6% QoQ | - | - | - |
The average 5 years interest of Akero Therapeutics was 8.57 per week. The last year interest of Akero Therapeutics compared to the last 5 years has changed by 14.47%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 6.98%.
There is not enough data for Efruxifermin NASH to provide analysis
There is not enough data for Efruxifermin NASH to provide correlation calculation
There is not enough data for Efruxifermin NASH to provide analysis
There is not enough data for Akero Therapeutics clinical trials to provide analysis
There is not enough data for Akero Therapeutics clinical trials to provide correlation calculation
There is not enough data for Akero Therapeutics clinical trials to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. Fibroblast growth factor 21 expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 27 | 101 274.1% QoQ | 180 78.2% QoQ | 97 -46.1% QoQ |
| 2020 | 179 563.0% YoY 84.5% QoQ | 173 71.3% YoY -3.4% QoQ | 139 -22.8% YoY -19.7% QoQ | 206 112.4% YoY 48.2% QoQ |
| 2021 | 145 -19.0% YoY -29.6% QoQ | 24 -86.1% YoY -83.4% QoQ | 65 -53.2% YoY 170.8% QoQ | 354 71.8% YoY 444.6% QoQ |
| 2022 | 92 -36.6% YoY -74.0% QoQ | 63 162.5% YoY -31.5% QoQ | 170 161.5% YoY 169.8% QoQ | 148 -58.2% YoY -12.9% QoQ |
| 2023 | 100 8.7% YoY -32.4% QoQ | 136 115.9% YoY 36.0% QoQ | 190 11.8% YoY 39.7% QoQ | 31 -79.1% YoY -83.7% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Fibroblast growth factor 21 was 10.04 per week. The last year interest of Fibroblast growth factor 21 compared to the last 5 years has changed by -17.43%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -17.76%.
There is not enough data for Metabolic disease treatments to provide analysis
There is not enough data for Metabolic disease treatments to provide correlation calculation
There is not enough data for Metabolic disease treatments to provide analysis
After 39 days of this quarter the interest is at 31.0. Based on that we can calculate that during remaining 52 days it will total up to 72.0. Akero Therapeutics news expected interest is significantly lower compared to same quarter last year (-61.5%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 91 | 207 127.5% QoQ | 72 -65.2% QoQ | 73 1.4% QoQ |
| 2020 | 47 -48.4% YoY -35.6% QoQ | 151 -27.1% YoY 221.3% QoQ | 102 41.7% YoY -32.5% QoQ | 163 123.3% YoY 59.8% QoQ |
| 2021 | 64 36.2% YoY -60.7% QoQ | 86 -43.0% YoY 34.4% QoQ | 91 -10.8% YoY 5.8% QoQ | 124 -23.9% YoY 36.3% QoQ |
| 2022 | 47 -26.6% YoY -62.1% QoQ | 63 -26.7% YoY 34.0% QoQ | 113 24.2% YoY 79.4% QoQ | 33 -73.4% YoY -70.8% QoQ |
| 2023 | 187 297.9% YoY 466.7% QoQ | 0 -100.0% YoY -100.0% QoQ | 135 19.5% YoY inf% QoQ | 76 130.3% YoY -43.7% QoQ |
| 2024 | 31 -83.4% YoY -59.2% QoQ | - | - | - |
The average 5 years interest of Akero Therapeutics news was 7.49 per week. The last year interest of Akero Therapeutics news compared to the last 5 years has changed by -23.23%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -36.81%.
There is not enough data for Akero Therapeutics stock price to provide analysis
There is not enough data for Akero Therapeutics stock price to provide correlation calculation
There is not enough data for Akero Therapeutics stock price to provide analysis
There is not enough data for Akero Therapeutics vs competitors to provide analysis
There is not enough data for Akero Therapeutics vs competitors to provide correlation calculation
There is not enough data for Akero Therapeutics vs competitors to provide analysis
There is not enough data for Akero Therapeutics careers to provide analysis
There is not enough data for Akero Therapeutics careers to provide correlation calculation
There is not enough data for Akero Therapeutics careers to provide analysis
There is not enough data for Akero Therapeutics contact to provide analysis
There is not enough data for Akero Therapeutics contact to provide correlation calculation
There is not enough data for Akero Therapeutics contact to provide analysis